For instance, bortezomib is a PI approved for the treatment of MM and MCL and in MM cell lines bortezomib has been shown to induce increased levels of phospho-eIF2α, ATF4 and the expression of the pro-apoptotic ATF4 target gene CHOP [84]. Here, EIF2A is linked to Miyoshi myopathy.